But there is controversial data from preclinical studies which focused on the effects of NSAIDs especially selective COX-2 inhibitors in AD and found that celecoxib has failed to show cognitive amelioration in the brains of AD patients (Sánchez-Sarasúa et al., 2022). The gene discussed is PTGS2; the disease is Alzheimer disease.